ArticleAntimicrobial agents and chemotherapy2014
Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antimicrobial resistance in Africa: a systematic review.BMC infectious diseases · 2017Pooled it
- Efficacy of antibiotic combinations in an experimental sepsis model with Pseudomonas aeruginosa.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Reliability of E-Tests and the Phoenix Automated Method in Assessing Susceptibility to IV Fosfomycin-Comparative Studies Relative to the Reference Method.Pathogens (Basel, Switzerland) · 2023Article
- Genomic analysis of Fosfomycin resistance in multi-drug resistant uropathogens and comparison ofIranian journal of microbiology · 2022Article
- Use of Fosfomycin Etest To DetermineJournal of clinical microbiology · 2021Article
- In Vitro Susceptibility of Multi-Drug ResistantPathogens (Basel, Switzerland) · 2021Article
- Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem-ResistantPharmaceuticals (Basel, Switzerland) · 2021Article
- Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates.Journal of clinical microbiology · 2020Article
- Effective Treatment for Uncomplicated Urinary Tract Infections with Oral Fosfomycin, Single Center Four Year Retrospective Study.Antibiotics (Basel, Switzerland) · 2020Article
- The combined antimicrobial activity of citrus honey and fosfomycin on multidrug resistantAIMS microbiology · 2020Article
- The Role ofJournal of clinical microbiology · 2019Article
- New microbiological aspects of fosfomycin.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019Review
- Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2018Article
- The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.BMC urology · 2017Article
- Fosfomycin: Resurgence of an old companion.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2016Review
- Fosfomycin.Clinical microbiology reviews · 2016Review
- Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2016Review
- Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database.Infectious diseases and therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fosfomycin may be a treatment option for multiresistant Gram-negative bacteria. This study compared susceptibility methods using 94 multiresistant clinical isolates. With agar dilution (AD), susceptibilities were 81%, 7%, 96%, and 100% (CLSI) and 0%, 0%, 96%, and 30% (EUCAST), respectively, for Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Enterobacter spp. Categorical agreement between Etest and AD for Enterobacteriaceae and A. baumannii was ≥80%. Disk diffusion was adequate only for Enterobacter. CLSI criteria for urine may be adequate for systemic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.